OncoRNA

This week Christophe Van Huffel and Jean-Pol Detiffe participated in the 1st General Assembly of #Med4Cure, the first Important Project of Common European Interest (IPCEI) in Health, hosted by #DGE alongside the EU Commission and committed Member States 🇫🇷🇧🇪🇪🇸🇮🇹🇭🇺🇸🇰. 🇪🇺 At OncoRNA, we’re proud to contribute to this pioneering IPCEI with our mRNA end-to-end project to build a state-of-the-art scientific and technological platform in Europe. Even more proud that only 13 companies were selected for funding, and OncoRNA is the only direct partner coming from Belgium 🇧🇪! 𝗠𝗲𝗱𝟰𝗖𝘂𝗿𝗲 𝗶𝘀 𝗱𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝘁𝗼: ✅ Deliver breakthrough innovations for diseases with limited or no treatment options ✅ Strengthen Europe’s preparedness for emerging health threats Let’s make #Med4Cure a game-changer for Europe's health innovation and competitiveness! 💡 #Innovation #Health #Europe #Competitiveness

Before Larry Ellison from Oracle announced the feasibility of producing personalized cancer vaccines using mRNA technology within 48 hours, we at OncoRNA had already designed a 3-week innovative process that takes patients from biopsy to the rapid production of targeted therapy, setting a new standard for precision medicine! 👉 Discover our innovation: https://oncorna.eu

Before Larry Ellison from Oracle announced the feasibility of producing personalized cancer vaccines using mRNA technology within 48 hours, we at OncoRNA had already designed a 3-week innovative process that takes patients from biopsy to the rapid production of targeted therapy, setting a new standard for precision medicine! 👉 Discover our innovation: https://oncorna.eu

🎧 We’re excited to unveil a new podcast series presented by OncoRNA! This series will spotlight our pioneering mRNA vaccine solution while exploring the current landscape and the promising future of personalized cancer vaccines. 🧬 Titled "𝗧𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗖𝗮𝗻𝗰𝗲𝗿 𝗩𝗮𝗰𝗰𝗶𝗻𝗲", this podcast serves as a practical and engaging platform for us to share our expertise, innovative solutions, and forward-looking perspectives on cancer vaccines. OncoRNA is thrilled to embrace this medium to connect with the scientific community and everyone interested in shaping the future of personalized medicine. Here is our first episode, let’s dive into the future of personalized cancer vaccines: https://lnkd.in/eJa5h_SG

💥𝗕𝗥𝗘𝗔𝗞𝗜𝗡𝗚 𝗡𝗘𝗪𝗦💥 We are delighted to announce the selection of OncoRNA by the European Commission as a highly innovative solution supported by the IPCEI Med4Cure project receiving up to €1 billion of State aid. Only 13 companies of all sizes were selected, and OncoRNA is the only direct partner coming from Belgium 🇧🇪! The IPCEI Med4Cure project aims at accelerating medical advancement and fostering the resilience of the EU health industry by enhancing drug discovery, in particular for unmet medical needs, and developing innovative and more sustainable production processes for pharmaceuticals. 🔬 💉 💊 👉 Read more: https://lnkd.in/eVKzrgFu